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Abstract Ectonucleotidases are ectoenzymes that hy-
drolyze extracellular nucleotides to the respective
nucleosides. Within the past decade, ectonucleotidases
belonging to several enzyme families have been
discovered, cloned and characterized. In this article,
we speciﬁcally address the cell surface-located mem-
bers of the ecto-nucleoside triphosphate diphosphohy-
drolase (E-NTPDase/CD39) family (NTPDase1,2,3,
and 8). The molecular identiﬁcation of individual
NTPDase subtypes, genetic engineering, mutational
analyses, and the generation of subtype-speciﬁc anti-
bodies have resulted in considerable insights into
enzyme structure and function. These advances also
allow deﬁnition of physiological and patho-physiologi-
cal implications of NTPDases in a considerable variety
of tissues. Biological actions of NTPDases are a
consequence (at least in part) of the regulated phos-
phohydrolytic activity on extracellular nucleotides and
consequent effects on P2-receptor signaling. It further
appears that the spatial and temporal expression of
NTPDases by various cell types within the vasculature,
the nervous tissues and other tissues impacts on several
patho-physiological processes. Examples include acute
effects on cellular metabolism, adhesion, activation and
migration with other protracted impacts upon develop-
mental responses, inclusive of cellular proliferation,
differentiation and apoptosis, as seen with atheroscle-
rosis, degenerative neurological diseases and immune
rejection of transplanted organs and cells. Future
clinical applications are expected to involve the devel-
opment of new therapeutic strategies for transplanta-
tion and various inﬂammatory cardiovascular,
gastrointestinal and neurological diseases.
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ERK extracellular regulated kinase
FAK focal adhesion kinase
MAP mitogen-activated protein
MAPK MAP kinase
NO nitric oxide
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phosphodiesterase
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PDGF platelet derived growth factor
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Introduction
Extracellular nucleotides modulate a multiplicity of
tissue functions including development, blood ﬂow,
secretion, inﬂammation and immune reactions. Indeed,
signaling via extracellular nucleotides has been recog-
nized for over a decade as one of the most ubiquitous
intercellular signaling mechanisms [1, 2]. Essentially
every cell in a mammalian organism leaks or releases
these mediators, and carries receptors for nucleotides
of which seven ionotropic (P2X) and at least eight
metabotropic (P2Y) receptor subtypes have been iden-
tiﬁed and characterized to date. Whereas P2X recep-
tors respond to ATP, P2Y receptors can be activated
by ATP, ADP, UTP, UDP, ITP, and nucleotide sug-
ars, albeit agonist speciﬁcity varies between subtypes
and the multiple animal species [3]. Depending on the
P2 receptor subtype and signaling pathways involved,
these receptors trigger and mediate short-term (acute)
processes that affect cellular metabolism, adhesion,
activation or migration. In addition, purinergic signal-
ing also has profound impacts upon other more
protracted responses, including cell proliferation, dif-
ferentiation and apoptosis, such as seen in atheroscle-
rosis, degenerative neurological diseases and in several
inﬂammatory conditions [2, 4, 5].
The effects of extracellular nucleotides appear to
overlap, at least in part, with those of vascular growth
factors, cytokines (inﬂammatory), adhesion molecules
and nitric oxide (NO). Nucleotide-mediated activation
may be also synergistic with polypeptide growth
factors (PDGF, bFGF) and insulin, the signaling being
mediated via phospholipase C and D, diacylglycerol,
protein kinase C, ERKs, phosphatidylinositol 3-kinases
(PI3K), MAP kinases (MAPK) and Rho [6–8]. The
situation concerning extracellular nucleotide-signaling
can be suitably contrasted with the unique speciﬁcity
of peptide hormones or vasoactive factors for often
single, deﬁned receptors [9, 10]. Within purinergic/
pyrimidinergic signaling events speciﬁcity is dictated
by three essential modulatory components: 1) The
derivation or source of the extracellular nucleotides [1,
11, 12]; 2) the expression of speciﬁc receptors for these
molecular transmitters (and for the nucleotide and
nucleoside derivatives) [13–16] (See also Molecular
Recognition Section of National Institutes of Health,
http://mgddk1.niddk.nih.gov/ also http://www.ensembl.
org/index.html and http://www.geocities.com/bioinfor-
maticsweb/speciesspeciﬁcdatabases.htm), and, 3) select
ectonucleotidases that dictate the cellular responses by
the stepwise degradation of extracellular nucleotides
to nucleosides [17–20].
Ensembles of ectonucleotidases, associated
receptors and signaling molecules
Within the past decade, ectonucleotidases belonging to
several enzyme families have been discovered, cloned
and functionally characterized by pharmacological
means. Speciﬁcally, we refer here to members of the
ecto-nucleoside triphosphate diphosphohydrolase (E-
NTPDase) family (EC 3.6.1.5) as ectoenzymes that
hydrolyze extracellular nucleoside tri- and diphos-
phates and have a deﬁned pharmacological proﬁle.
Most notably, in many tissues and cells, NTPDases
comprise dominant parts of a complex cell surface-
located nucleotide hydrolyzing and interconverting
machinery. This ensemble includes the ecto-nucleotide
pyrophosphatase phosphodiesterases (E-NPPs), NAD-
glycohydrolases, CD38/NADase, alkaline phospha-
tases, dinucleoside polyphosphate hydrolases, adeny-
late kinase, nucleoside diphosphate kinase, and
potentially ecto-F1–Fo ATP synthases [21–25] that
may interact in various tissues and cellular systems.
The ectonucleotidase chain or cascade, as initiated
by NTPDases can be terminated by ecto-50-nucleotid-
ase (CD73; EC 3.1.3.5) with hydrolysis of nucleoside
monophosphates [26]. Together, ecto-50-nucleotidase
and adenosine deaminase (ADA; EC 3.5.4.4), another
ectoenzyme that is involved in purine salvage path-
ways and converts adenosine to inosine, closely
regulate local and pericellular extracellular and plasma
concentrations of adenosine [10, 27].
Several of these ectonucleotidase families and
additional functions of NTPDases [28–30]a r e
addressed elsewhere in this issue in detail. This review
focuses on the surface-located mammalian members of
the E-NTPDase protein family. It starts with a brief
introduction of molecular structure and functional
properties, followed by an analysis of the physiological
and pathophysiological roles at various sites with an
emphasis on vasculature and neural tissues.
Molecular identities unraveled
The literature on the molecular and functional char-
acterization of the E-NTPDase family has been
intensively reviewed [18–22, 31–36] and will not be
410 Purinergic Signalling (2006) 2:409–430repeated here in detail. Our intent is to summarize
principal properties of the enzymes that will be of use
for the reader new to this ﬁeld.
Eight different ENTPD genes (Table 1 and Fig. 1)
encode members of the NTPDase protein family. Four
of the NTPDases are typical cell surface-located
enzymes with an extracellularly facing catalytic site
(NTPDase1, 2, 3, 8). NTPDases 5 and 6 exhibit intracel-
lular localization and undergo secretion after heterolo-
gous expression. NTPDases 4 and 7 are entirely
intracellularly located, facing the lumen of cytoplasmic
organelles (Fig. 1). The molecular identiﬁcation of
individual NTPDase subtypes, genetic engineering,
mutational analyses, and the generation of subtype-
speciﬁc antibodies have not only led to considerable
insight into enzyme structure and function. These
advances have also deﬁned physiological and patho-
physiological functions of NTPDases in a considerable
variety of tissues.
The presence of ATP and/or ADP hydrolyzing
activity at the surface of many cell types had been
recognized for several decades [17, 37–40]. However,
the molecular identity of the ﬁrst member of the E-
NTPDase family (NTPDase1) was not unraveled and
determined until the mid-1990s. The prototypic mem-
ber of the enzyme family had ﬁrst been cloned and
sequenced as a lymphocyte cell activation (CD39)
antigen of undetermined function [41]. Final success
came from three independent approaches. Handa and
Guidotti [42] puriﬁed and cloned a soluble ATP
diphosphohydrolase (apyrase) from potato tubers and
noted that this protein was related not only to similar
enzymes of some protozoans, plants and yeast but
also to human CD39. They also recognized conserved
sequence domains and the relation to members of the
actin-hsp70-hexokinase superfamily. This was then
followed by the functional expression of human
CD39 and the demonstration that this protein was in
fact an ecto-apyrase [43]. In parallel, ectonucleoti-
dases (termed ATP diphosphohydrolases) from por-
cine pancreas and bovine aorta were puriﬁed. The
partial amino acid sequences for both ATP diphos-
phohydrolases revealed identity with the cloned cDNA
sequence of CD39 [44]. The cDNA was isolated
from human endothelial cells and functional, throm-
boregulatory studies conﬁrmed that the dominant
vascular ectonucleotidase (ATP diphosphohydrolase)
activity was identical to the previously described and
cloned human CD39 [44]. Several internal peptide
sequences obtained from the puriﬁed human placental
ATP diphosphohydrolase [45] revealed that in retro-
spect this protein was also identical to CD39.
It was originally thought that there existed a single
ectonucleotidase of the NTPDase type with potential
post-translational modiﬁcations [46]. However, a
close molecular relative was soon cloned that re-
Table 1 Nomenclature of mammalian members of the E-NTPDase family and chromosomal localization
Protein name Additional names Gene name
human, mouse
Chromosome location
human, mouse
Accession number
human, mouse
NTPDase1 CD39, ATPDase,
ecto-apyrase [43, 44]
ENTPD1, Entpd1 10q24, 19C3 U87967, NM_009848
NTPDase2 CD39L1, ecto-ATPase
[49, 109, 252]
ENTPD2, Entpd2 9q34, 2A3 AF144748, AY376711
NTPDase3 CD39L3, HB6
[50, 177]
ENTPD3, Entpd3 3p21.3, 9F4 AF034840, AY376710
NTPDase4 UDPase, LALP70
[253, 254]
ENTPD4, Entpd4 8p21, 14D1 AF016032, NM_026174
NTPDase5 CD39L4,
ER-UDPase, PCPH
[137, 255, 256]
ENTPD5, Entpd5 14q24, 12E (12D1)
a AF039918, AJ238636
NTPDase6 CD39L2 [257–259] ENTPD6, Entpd6 20p11.2, 2G3 AY327581, NM_172117
NTPDase7 LALP1 [260] ENTPD7, Entpd7 10q24, 19D1 (19C3)
a AF269255, AF288221
NTPDase8 liver canalicular
ecto-ATPase,
hATPDase [52, 174]
ENTPD8, Entpd8 9q34, 2A3 AY430414, AY364442
Information is provided for the human genome from GenBank (http://www.ncbi.nlm.nih.gov) and mouse genome informatics (MGI)
for the mouse genome (http://www.informatics.jax.org/). Since the mouse genome represents a composite assembly that continues to
undergo updates and changes from build to build, the computed map locations may be corrected in the future.
aFor mouse Entpd5 and Entpd7, the BLAST analysis displayed in Map Viewer indicates a different map location (in brackets) when
compared with the mapping data reported on MGI records using cytoband information based on experimental evidence.
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NTPDase2) rather than of an ecto-ATP diphosphohy-
drolase [47, 48]. Further human genomic analysis of
expressed sequence tags (ESTs) allowed the identiﬁ-
cation of additional members of the gene family [49–
51]. These genes were originally named CD39L(ike)1
to CD39L4. Then followed the identiﬁcation, cloning
and functional expression of all members of the E-
NTPDase family, the last to date being NTPDase8
[52].
Potential splice variants have been isolated for the
surface-located NTPDase1 and NTPDase2 [for refer-
ences see 34, 53]. It should be further noted that
heterologous expression of potential splice variants
does not necessarily result in the formation of a
functional protein [54].
The initially proposed nomenclature [50] has been
somewhat confusing as it did not meet with generally
accepted norms for human cell differentiation mole-
cules [55]. While CD39 (now NTPDase1) indeed
belongs to the cluster of differentiation antigens,
CD39L1 (NTPDase2), CD39L3 (NTPDase3),
CD39L4 (NTPDase5) and CD39L2 (NTPDase6) do
not. Scientists at the Second International Workshop
on Ecto-ATPases proposed that all E-NTPDase family
members be termed as NTPDase proteins and classi-
ﬁed in order of discovery and characterization [34, 56].
The CD39 nomenclature should fall away for all but
the prototypic member NTPDase1 that already has a
long history of use in the Immunology and Oncology
ﬁelds. Further revisions are however inevitable.
Catalytic properties
The individual NTPDase subtypes differ in cellular
location and functional properties. The four cell
surface-located forms (NTPDase1,2,3,8) can be differ-
entiated according to substrate preference, divalent
cation usage and product formation. All surface-
located NTPDases require Ca
2+ or Mg
2+ ions in the
millimolar range for maximal activity and are inactive
in their absence [34, 57]. They all hydrolyze nucleoside
triphosphates including the physiologically active ATP
and UTP. Notably, the hydrolysis rates for nucleoside
diphosphates vary considerably between subtypes
(Figs. 1 and 2). Whereas NTPDase1 hydrolyzes ATP
and ADP about equally well, NTPDase3 and
NTPDase8 reveal a preference for ATP over ADP as
substrate. NTPDase2 stands out for its high preference
for nucleoside triphosphates and therefore has previ-
ously also been classiﬁed as an ecto-ATPase [34, 57].
In contrast to NTPDase1 and NTPDase2, murine
NTPDase3 and NTPDase8 are preferentially activated
by Ca
2+ over Mg
2+ [52, 58, 59]. Presumably, differences
in sequence but also in secondary, tertiary and
quaternary structure account for differences between
subtypes in the catalytic properties [60, 61].
Fig. 1 Hypothetical phylogenetic tree derived for 22 selected members of the E-NTPDase family (NTPDase1 to NTPDase8) from rat
(r), human (h) and mouse (m), following alignment of amino acid sequences. The length of the lines indicates the differences between
amino acid sequences. The graph depicts a clear separation between surface-located (top) and intracellular (bottom) NTPDases. In
addition, the major substrate preferences of individual subtypes and the predicted membrane topography for each group of enzymes is
given (one or two transmembrane domains, indicated by barrels). Modiﬁed from [59].
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most directly to AMP with the transient production of
minor amounts of free ADP (Fig. 2). This functional
property largely circumvents activation of P2Y-recep-
tors for nucleoside diphosphates. Interestingly, signif-
icant amounts of UDP are accumulated when UTP is
hydrolyzed by NTPDase1 [57]. In contrast, ADP is
released upon ATP hydrolysis by NTPDase2, then
accumulates and is slowly dephosphorylated to AMP.
On the one hand, this results in the removal of agonists
for nucleoside triphosphate-sensitive P2Y-receptors
(Fig. 2). On the other hand, it generates agonists for
nucleoside diphosphate-sensitive receptors such as
platelet P2Y1 and P2Y12 receptors [62]. The actions
of NTPDase3 and NTPDase8 result in intermediate
patterns of product formation, leading to a transient
accumulation of diphosphonucleosides with the simul-
taneous presence of triphosphonucleosides.
Principal structural features
The hallmarks of all NTPDases are the ﬁve highly
conserved sequence domains known as Fapyrase con-
served regions_, abbreviated and termed ACR1 to
ACR5 [42, 63, 64] that are involved in the catalytic
cycle. This notion is supported by a considerable
variety of deletion and mutation experiments [for
reviews see 30, 34, 64–68].
NTPDases share two common sequence motifs with
members of the actin/HSP70/sugar kinase superfamily,
the actin-HSP 70-hexokinase b-a n dg-phosphate
binding motif [(I/L/V)X(I/L/V/C)DXG(T/S/G)(T/S/
G)XX(R/K/C)] [42, 47, 69, 70], with the DXG
sequence strictly conserved. These motifs are identi-
ﬁed in ACR1 and ACR4. Furthermore, there are
striking similarities in secondary structure with mem-
bers of the actin/HSP70/sugar kinase superfamily [30,
Fig. 2 Cell surface-located catabolism of extracellular nucleotides and potential activation of receptors for nucleotides (P2 receptors)
and adenosine (P1 receptors). The ﬁgure depicts the principal catalytic properties of members of the E-NTPDase family and of ecto-
50-nucleotidase. NTPDases sequentially convert ATP to ADP + Pi and ADP to AMP + Pi. NTPDase1 is distinct among these enzymes
as it dephosphorylates ATP directly to AMP without the release of signiﬁcant amounts of ADP. Hydrolysis of the nucleoside
monophosphate to the nucleoside is catalyzed by ecto-50-nucleotidase. NTPDases, NPPs and alkaline phosphatase sometimes co-exist
and it seems likely that they can act in concert to metabolize extracellular nucleotides. ATP can activate both P2X receptors and
subtypes P2Y receptors whereas UTP activates subtypes of P2Y receptors only. After degradation, ADP or UDP may activate
additional subtypes of P2Y receptors. The adenosine formed can potentially act on four different types of P1 receptors and is either
deaminated to inosine or directly recycled via nucleoside transporters. Bottom: Proﬁles of nucleotide hydrolysis and substrate formation
by plasma membrane-located NTPDases. The ﬁgure compares catalytic properties of human and murine NTPDase1,2,3 and 8, following
expression in COS-7 cells. The principal catalytic properties of the respective human and murine enzymes are similar. ATP (&), ADP
(Í), AMP (r). Modiﬁed from [57].
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photransferase or hydrolase activity, depend on diva-
lent metal ion and tend to form oligomeric structures.
In spite of negligible global sequence identity they
share the principal structure of two major domains (I
and II, possibly resulting from gene duplication) of
similar folds on either side of a large cleft. They reveal
similar conserved secondary structure topology
(b1b2b3a1b4a2b5a3) repeated in each domain and fold
into a pocket for substrate binding at the bottom [59].
Presumably, NTPDases share not only secondary
structure but also major elements of tertiary structure
with members of the actin/HSP70/sugar kinase super-
family (Fig. 3). Homology modeling of the NTPDase3
sequence reveals high degrees of structural fold
similarity with a bacterial exopolyphosphatase (PDB
1T6C) that further reﬁne structural predictions for
members of the E-NTPDase family [30, 72].
NTPDases readily form homo-oligomeric assem-
blies. NTPDase1 to NTPDase3 were found as dimers
to tetramers [29, 64, 73–78]. In contrast to the P2X
receptors that share a similar membrane topography,
hetero-oligomeric complexes between NTPDases
have not been reported, to date. Oligomeric forms
reveal increased catalytic activity [73, 75, 76] and the
state of oligomerization can affect catalytic properties
[77, 78].
NTPDase1,2,3, and 8 are ﬁrmly anchored to the
membrane via two transmembrane domains that in
the instance of NTPDase1 are important for main-
taining catalytic activity and substrate speciﬁcity [29,
64, 79]. The two transmembrane domains interact both
within and between monomers. They may also under-
go coordinated motions during the process of nucleo-
tide binding and hydrolysis [29, 61]. This could in turn
induce conformational changes [80] involving move-
ment of the two major domains (I and II) relative
to each other (Fig. 3). Alterations in quarternary struc-
ture and subunit interactions may thus affect the impact
or interaction of ACRs involved in substrate binding
and hydrolysis. Whether posttranslational modiﬁca-
tions such as protein phosphorylation contribute to this
dynamic behavior remains to be investigated.
Functional modiﬁcations
Biologically active NTPDase1 is subject to differential
forms of surface modiﬁcation under conditions of
oxidative stress that inhibit enzymatic activity, as
inﬂuenced by unsaturated fatty acids [81, 82]. It also
undergoes limited proteolysis that increases enzyme
activity and differential glycosylation reactions that
appear to be required for membrane expression [64].
Since the surface-located ATP-hydrolyzing members
of the NTPDase family pass through the endoplasmic
reticulum and Golgi apparatus, the associated catalytic
activity might abrogate ATP-dependent luminal func-
tional processes. NTPDase1 becomes catalytically
active on reaching the cell surface and glycosylation
reactions appear crucial in this respect [83].
The N-terminal intracytoplasmic domain of NTP-
Dase1 is palmitoylated. Truncated forms of NTPDase1
lacking the N-terminal intracytoplasmic region and the
associated Cys13 residue, are not subject to palmi-
toylation. This post-translational modiﬁcation appears
to be constitutive and to contribute to the integral
membrane association of this ectonucleotidase in lipid
rafts [84–86]. This raises the possibility that NTPDase1
may be recycled to and from cell membranes via
sequential actions of putative palmitoyltransferases
and palmitoyl-protein thioesterases [87], in order to
ﬁne tune and modulate purinergic signaling responses.
In contrast to NTPDase1 and NTPDase3, NTPDase2
does not have the required intra-cytoplasmic Cys to
undergo this post-translational modiﬁcation. The po-
tential multimerization of NTPDase1 [35] may be
Fig. 3 Hypothetical membrane topology of a surface-located
NTPDase with two transmembrane domains. A comparison of
the conserved secondary structure reveals duplicate conservation
of two major domains related to subdomains Ia and IIa of actin,
and other members of the actin/HSP70/sugar kinase superfamily
[59]. In contrast to the other members of the superfamily,
surface-located NTPDases are anchored to the plasma mem-
brane by terminal hydrophobic domains. The ﬁgure takes into
account the close distance of the N- and C-terminus of actin at
domain I and the binding of ATP (red) in the cleft between
domains I and II [80]. These two domains are expected to
undergo conformational changes involving movement relative to
each other.
414 Purinergic Signalling (2006) 2:409–430facilitated by acylation with intermolecular interac-
tions within the cholesterol and sphingolipid-rich
microdomains of the plasma membrane [88]. Experi-
ments using endothelial cells from caveolin-1 deﬁcient
mice suggest that caveolae are not essential for the
enzymatic activity or for the targeting to the plasma
membrane of NTPDase1. However, cholesterol deple-
tion results in a strong inhibition of the enzyme [86].
The targeting of palmitoylated NTPDase1 to lipid rafts
could inﬂuence deﬁned G-protein coupled receptors
within this plasmalemmal microenvironment and thus
regulate cellular signal transduction pathways. Fur-
thermore, the caveolar co-localization of ecto-50-nu-
cleotidase, P2 receptors, and NTPDase1 could serve to
modulate signaling via both ATP and adenosine at the
cell surface and possibly also within endosomal com-
partments [20].
Transcriptional regulation of expression
Members of the E-NTPDase family are constitutively
expressed in many tissues. To date, there is only
scattered evidence on promoters and the factors
controlling NTPDase expression [22]. The transcrip-
tion of NTPDase1/CD39 is constitutive in venous,
arterial and certain non-fenestrated microvascular
endothelium and certain immune cells e.g., B cells,
dendritic cells and deﬁned T-cell subsets [20, 89]. The
modulated expression of NTPDase1 has been closely
associated with inﬂammatory cytokines, oxidative
stress and hypoxia in vitro and in vivo [19, 90].
Expression of NTPDase1 is increased in differenti-
ating melanomas followed by a gradual decrease with
tumor progression [91] and enhanced NTPDase1
activity of stimulated endothelial and mesangial cells
is downregulated by glucocorticosteroids [92]. Activity
of Fecto-ATP diphosphohydrolase_ in human endothe-
lial cells in-vitro is increased by aspirin [93]a n d
glomerular Fecto-ATP diphosphohydrolase_ immuno-
reactivity might well be modulated by estradiol [94].
Transcription of NTPDase2 in mouse hepatoma
cells is inducible by 2,3,7,8-tetrachlorodibenzo-p-diox-
in (TCDD) [95]. These cells contain both constitutive
and TCDD-inducible NTPDase2 activity. The NTPD-
ase2 core promotor reveals constitutive activity that is
independent of TCDD [96]. TCDD does not increase
expression of NTPDase1, NTPDase3 or other ectonu-
cleotidases and apparently fails to induce NTPDase2
in a variety of other cell lines derived from varying
species [97]. In rat Sertoli cells, NTPDase2 is upregu-
lated by follicle-stimulating hormone and cAMP [98]
and it is selectively downregulated in biliary cirrhosis
[99]. Human epidermoid carcinoma cells increase the
cascade for extracellular nucleotide hydrolysis when
periodically treated with extracellular ATP, suggesting
that the substrate itself may affect the expression of its
own hydrolysis chain [100].
Inhibitors
A considerable number of compounds alter and in-
hibit extracellular nucleotide hydrolysis by NTPDases.
These include non-hydrolysable nucleotide analogues
and inhibitors of P2 receptors. Ideally, NTPDase in-
hibitors should not be P2 receptor agonists or antago-
nists and not be subject to dephosphorylation by the
ectoenzyme [22, 101, 102]. The only commercially
available compound reported to effectively inhibit hy-
drolysis of ATP in a variety of tissues without sig-
niﬁcantly acting on purinoceptors is the structural
analogue of ATP, ARL 67156 (FPL 67156) (6-N,
N-diethyl-D-b,g-dibromomethylene ATP) [103–
105]. Other potential inhibitors include 8-thiobutyl-
adenosine 50-triphosphate (8-BuS-ATP) [106]a n d
1-naphthol-3, 6-disulfonic acid (BG0136) [101]. Period-
ate-oxidized ATP inhibits ecto-ATPase activity in
1312N1 human astrocytoma cells [107] and Gadolini-
um ions have been found to effectively inhibit the
ecto-nucleoside triphosphate diphosphohydrolase
from Torpedo electric organ as well as potato apyrase
[108].
It is noteworthy that the potency of inhibitors can
vary considerably between individual members of the
E - N T P D a s ef a m i l y[ 109–111]. This necessitates a
functional evaluation of each inhibitor for the enzyme
investigated in a given tissue or cell type. The failure to
develop speciﬁc inhibitors remains a major impedi-
ment to ongoing discoveries.
Principal functional contexts
Cell surface-located NTPDases are considered to be of
major importance for controlling the availability of
extracellular nucleotide agonists at P2 receptors. They
also contribute to recycling of nucleosides derived
from extracellular nucleoside phosphates and meta-
bolic salvage pathways. The number of studies that
deﬁne a functional impact of individual NTPDases in
purinergic signaling in situ is limited and has been
dependent to date on global genetic modiﬁcations of
mice and swine to delete or upregulate the NTPDase
or P2 gene of interest [20]. Subtype-speciﬁc inhibitors,
siRNA approaches, and animals in which the encoding
Purinergic Signalling (2006) 2:409–430 415gene can be inactivated or selectively induced in
speciﬁc tissues will be of major importance.
There is increasing experimental evidence that
ectonucleotidases compete with P2 receptors for a
limited pool of endogenously released nucleotide [112,
113] and – by hydrolyzing released nucleotide –
terminate or modulate the function of P2 receptors
[114–116]. Portal ﬁbroblasts regulate P2Y receptor-
mediated bile duct epithelial proliferation via expres-
sion of NTPDase2 [117] (see liver section, below).
NTPDases functionally interact with P2Y-receptors
[112] and may also co-localize with these G-protein-
coupled receptors (GPCR) in lipid rafts and possibly
caveolae [118–121]. The modulatory effects of
NTPDases are complex as the enzymes differentially
regulate agonist availability in a process that is
dependent upon P2 receptor subtype by either degrad-
ing ATP/UTP or by generating ADP/UDP (Fig. 2).
Recent experiments suggest that plasma membrane-
bound NTPDases may have functions distinct from
their catalytic properties alone. In a yeast two-hybrid
system using techniques developed by Zhong for yeast
apyrases [122], the N-terminus of human NTPDase1
(used as bait protein) has been shown to interact with
truncated Ran Binding Protein M (RanBPM, other-
wise known as RanBP9, NM_005493) in the human
library screened [122a]. RanBPM contains conserved
SPRY (repeats in splA and RyR) domains that appear
to be crucial for the interaction with NTPDase1 and is
preferentially distributed in human heart tissues [123].
RanBPM is known to interact with Sos and regulate
ERK/Ras signaling. NTPDase1 interacts with
RanBPM to directly modulate Ras activation and
cellular proliferation in liver regeneration following
partial hepatectomy [124].
The N-termini of NTPDases also have consensus
sequences for protein phosphorylation by protein
kinase C [47] that could have additional functional
impacts. Furthermore, the C-terminal sequence of
NTPDase1 contains a putative PDZ domain (-K-D-
M-V). This may have utility in determining interac-
tions with select P2Y receptors e.g., the purinergic
P2Y1 and P2Y2 receptors that terminate in -D-T-S-L
and -D-I-R-L, respectively [125]. PDZ domains are
most often found in combination with other protein
interaction domains (for instance, SH3, PTB, WW),
participating in complexes that facilitate signaling or
determine the localization of receptors [126–128].
Finally, the general membrane topography of
NTPDase1 and oligomeric assembly resemble the
morphology of channel forming proteins such as P2X
nucleotide receptors and members of the epithelial Na
+
channel/degenerin gene superfamily [129]. This raises
the question whether, in addition to their catalytic
activity, NTPDases could function as channels. Re-
lease of ATP from Xenopus oocytes induced by hyper-
polarizing pulses requires functional ecto-ATPase
activity [130]. To what extent this functional property
is shared by the structurally related NTPDase2,
NTPDase3 and NTPDase8 has not been investigated.
Vasculature
The normal vascular endothelium provides a barrier
that separates blood cells and plasma factors from
highly reactive elements of the deeper layer of vessel
wall. The vessel wall maintains blood ﬂuidity and
promotes ﬂow by inhibiting coagulation, platelet
activation and promoting ﬁbrinolysis [131]. These
properties are governed by important thromboregula-
tory mechanisms; key biological activities of the
vasculature have been already identiﬁed and shown
to be ecto-nucleotide catalysts that generate the
respective nucleosides by phosphohydrolysis [19, 82].
The dominant ectonucleotidases of the vasculature
have now more fully been characterized as NTPDases.
This important biological property expressed by the
endothelium and associated cells is responsible for the
regulation of extracellular and plasma levels of nucleo-
tides [20, 44, 82, 132, 133].
Over the past decade, extracellular nucleotides have
been recognized as important mediators of a variety of
processes including vascular inﬂammation and throm-
bosis with varying impacts in different systems [19].
Adenosine and ATP mediated effects or mechanisms
can be implicated in the local control of vessel tone as
well as in individual vascular cell migration, prolifer-
ation and differentiation. As an example, ATP may be
released from sympathetic nerves (see later sections)
and results in constriction of vascular smooth muscle
through effects mediated by P2X receptors. In con-
trast, ATP released from endothelial cells during
changes in ﬂow (shear stress) or following exposure
to hypoxic conditions activates P2Y receptors in a
paracrine manner to release NO, resulting in vessel
relaxation. Any nucleotide released will be ultimately
hydrolyzed to adenosine and will result in vasodilata-
tion via the effects of smooth muscle P1 receptors.
P2X receptors also appear on vascular cells and are
associated with changes in cell adhesion and perme-
ability [2]. These cellular processes and nucleotide-
triggered events are modulated during angiogenesis
(Fig. 4) and inﬂuence the development of atheroscle-
rosis and restenosis following angioplasty [2, 113, 134–
136].
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vasculature [112]. Other NTPDases associated with
the vasculature are the cell-associated NTPDase2 and
the soluble monocyte expressed NTPDase5 [32, 50,
137]. The phosphohydrolytic reaction of NTPDase1
limits the platelet activation response that is depen-
dent upon the paracrine release of ADP and activation
of speciﬁc purinergic receptors [81, 132, 138]. In
contrast, NTPDase2, a preferential nucleoside triphos-
phatase, activates platelets by converting the compet-
itive antagonist (ATP) of platelet ADP-receptors to
the speciﬁc agonist of the P2Y1, and P2Y12 recep-
tors. In keeping with these biochemical properties,
NTPDase1 is dominantly expressed by endothelial
cells and the associated vascular smooth muscle where
it serves as a thromboregulatory factor. In contrast,
NTPDase2 is associated with the adventitial surfaces
of the muscularized vessels, microvascular pericytes of
some tissues and organs as the heart and the stromal
cells and would potentially serve as a hemostatic factor
[62].
Extracellular nucleotide stimulation of P2 receptors
represents components of platelet, endothelial cell and
leukocyte activation that culminate in vascular throm-
bosis and inﬂammation in vivo [19]. In these inﬂam-
matory settings, with oxidant endothelial injury,
NTPDase1 biochemical function is substantially, albeit
temporarily, decreased because of post-translational
changes; reconstitution of vascular NTPDase activity
occurs following transcriptional upregulation of CD39
in endothelium [82, 139]. This functional change may
relate, at least in part, to alterations in acylation and
associated membrane lipid association with conse-
quent disruption of multimer structure. Interestingly,
palmitate supplementation may protect against loss of
NTPDase activity following cellular activation in vitro
[81]. These observations may provide several avenues
of research to augment NTPDase activity within the
vasculature at sites of injury [134].
Mechanisms of endothelial cell activation
by nucleotides
ATP and UTP increases intracellular calcium levels,
results in cytoskeletal rearrangements and stimulates
phosphorylation of several proteins in human endo-
thelial cells (EC) that are also associated with integrin
signaling [140–142]. These include the focal adhesion
kinase (FAK) and paxillin, proline-rich tyrosine kinase
2 (Pyk2) (also named related adhesion focal tyrosine
kinase, RAFTK) and p38 MAP kinase. Further, UTP
preferentially increases EC migration in a PI3-kinase
and ERK-dependent manner. Moreover, extracellular
nucleotide-mediated EC activation involves cytoske-
letal rearrangements and increases in cell motility,
comparable to that seen with ligation of integrins by
extracellular matrix proteins [143]. These phenotypic
changes (seen in both nucleotide- and matrix-mediated
activation) are associated with tyrosine phosphoryla-
tion of FAK, paxillin and p130 Crk-associated sub-
strate (p130
cas) and down-stream activation of p38
MAP kinases. FAK has been implicated to play an
important role in integrin-mediated signal transduction
pathways [144], suggesting that P2-receptors are im-
plicated in Finside-out_ integrin signaling in EC, as well
as platelets [20, 112].
Therapeutic considerations
To test how extracellular nucleotide-mediated sig-
naling inﬂuences pathophysiological events, several
techniques have been developed and validated to
Fig. 4 Angiogenesis with expression of NTPDase1 in the vasculature of syngeneic islet transplants. Mouse islets were prepared from
wild type and Entpd1 null mice, as described by T. Maki et al. and transplanted under the renal capsule [261]. Islets were harvested at
four weeks (n = 4 per group) and stained for NTPDase1 immunoactivity and other markers of EC. Substantially diminished levels of
CD31 staining vascular elements were also present in null to Entpd1 null grafts, indicating a defect in new vessel growth (not depicted
here). A) Wild type to wild type showing grafted islet vasculature staining for NTPDase1 with adjacent normal renal vascular pattern.
B) Wild type to null mouse showing intrinsic vasculature of islet has persisted within the graft and even entered the NTPDase1 null
renal parenchyma. C) Null to wild type grafts showing inﬁltrating macrophages and NTPDase1 positive endothelium migrating from
recipient (conﬁrmed by other stains; not shown).
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and to study conditions of inﬂammatory stress. The
ﬁrst mutant mouse derived and studied concerned the
global deletion of the gene encoding the dominant
ectonucleotidase NTPDase1 (Entpd1,cd39). The mu-
tant mice exhibit major perturbations of P2 receptor-
mediated signaling in the vasculature and immune
systems [19, 89, 145]. These phenomena manifest as
hemostatic defects, thromboregulatory disturbances,
heightened acute inﬂammatory responses with a fail-
ure to generate cellular immune responses that are all
associated with vascular endothelium, monocyte, den-
dritic cell and platelet integrin dysfunction [20, 112,
134].
The therapeutic potential of NTPDase1 to regulate
P2 receptor function in the vasculature and mitigate
against thrombotic/inﬂammatory stress has been fur-
ther established by the generation of NTPDase1
transgenic mice and swine [20, 146], the use of
adenoviral vectors to upregulate NTPDase1 in cardiac
grafts [147] and the use of soluble derivatives of
NTPDase1 and apyrases [133, 148]. The beneﬁcial
effects of administered NTPDases have been deter-
mined in several animal models of vascular inﬂamma-
tion [148, 149]. Exogenous infusions of soluble
NTPDases are able to rescue Entpd1-deﬁcient mice
from systemic toxicity induced by ischemia reperfusion
injury and after stroke induction [145, 150].
Angiogenesis requires the dynamic interaction of
endothelial cell proliferation and differentiation with
orchestrated interactions between extracellular matrix
and surrounding cells (such as vascular smooth muscle
and/or pericytes) [151–153]. NTPDase1 appears crucial
in the co-ordination of angiogenic responses in inﬂam-
mation, organ remodeling and transplantation [20,
134]. For example, in syngeneic pancreatic islet
transplantation, the maintenance and revascularization
of grafted islets appears dependent upon expression of
NTPDase1 by the developing vasculature within the
islet (Fig. 4).
In summary, multiple experimental studies largely
revealbeneﬁcialeffectsofover-expressionofNTPDases
within the vasculature, or by their pharmacological
administration [20, 133]. Clinical studies of these
soluble thromboregulatory factors are in planning [20,
154, 155].
Immune system
There are multiple P2X and P2Y receptor subtypes
expressed by monocytes and dendritic cells, whereas
lymphocytes express only P2Y receptors [2]. NTP-
Dase1/CD39 was ﬁrst described as a B lymphocyte
activation marker and also shown to be expressed on
activated T cells [156, 157] and dendritic cells [89].
The CD39 enzymatic function on dendritic cells is
involved in the recruitment, activation and polariza-
tion of naive T cells. ATP is released by CD4
+ and
CD8
+ T cells upon stimulation with Con A or anti-
CD3 mAb while CD39 functions as an additional
recognition structure on haptenated target immuno-
cytes for HLA-A1-restricted, hapten-speciﬁc cytotoxic
T cells [156, 157].
In cd39 null mice, there are major defects in
dendritic cell function antigen presentation and T-cell
responses to haptens (type IV hypersensitivity reac-
tions) [19, 89]. Immunocyte-associated CD39 may play
an immunoregulatory role by hydrolyzing ATP (and
perhaps ADP) released by T cells during antigen pre-
sentation and thereby generating adenosine [19, 89,
158]. Ectoenzymes, including ectonucleotidases, are
known to play an important role in leukocyte trafﬁck-
ing (for an excellent review on this topic, see [159]).
Recent work has indicated that regulatory CD4 + ve
CD25 + ve T cells (Treg cells) play important roles in
the maintenance of immunological reactivity and
tolerance [160]. The selective expression of CD39 by
Treg and the question whether this ectonucleotidase
and/or extracellular nucleotides inﬂuence(s) the func-
tion of these interesting cells is a focus of current work.
Digestive and renal systems
Released nucleotides are polarized and do not re-enter
cells. They have to be transformed into the corre-
sponding nucleosides that enter cells via speciﬁc trans-
porters to rebuild nucleoside pools. If this did not occur,
they would be lost from the metabolic pool. The same
may pertain to dietary ingestion of nucleotides where
NTPDases are potential participants in the digestion of
exogenous nucleotides and intestinal function. In addi-
tion, extracellular nucleotide and adenosine receptors
are highly expressed in the digestive and renal systems,
so these molecules are likely to have homeostatic
functions [2].
An important nucleotide-mediated mechanism that
seems common to various epithelia, as well as to
hepatocytes, involves the autocrine regulation of cell
volume by ATP via P2 receptors [161, 162]. As P2 re-
ceptors are expressed by epithelia in a polarized
manner and can be linked to several digestive and
homeostatic functions [163, 164], the presence of
NTPDases in the immediate environment may serve
as regulatory switches.
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In the liver, extracellular nucleotides are potentially
involved in several functional contexts [161]. There is
evidence that extracellular nucleotides regulate glyco-
genolysis through activation of glycogen phosphory-
lase and inactivation of glycogen synthase by inhibition
of the glucagon effect on cAMP and by the activation
of phospholipase D [165, 166]. In addition, nucleotides
may be involved in the regulation of canalicular
contraction and bile ﬂow [167–169]. Concentrations
of canalicular adenine nucleotides in bile samples and
efﬂuents from hepatic cell lines are estimated to be
around 0.1 to 5 mM[ 161, 168]. Hepatocytes and bile
duct cells have been shown to interact and communi-
cate via local ATP release in vitro [170]. Extracellular
ATP acts as a hepatic mitogen and activates JNK
signaling and hepatocyte proliferation both in vitro
and in vivo [171].
Several ectonucleotidases are expressed in liver. Of
the nucleotide pyrophosphatase/phosphodiesterases,
NPP1 (PC-1) is expressed on the basolateral mem-
brane of hepatocytes while the closely related NPP3
(B10) has a predominant canalicular in distribution
[172, 173]. NTPDase1 is highly expressed on larger
vessels and more weakly on sinusoids as well as in
Kupffer cells [174]. In the quiescent liver, NTPDase2 is
expressed by cells of the subendothelium of veins and
adventitial cells of arteries, but not in sinusoids. In
addition, NTPDase2 is expressed by portal ﬁbroblasts
near basolateral membranes of bile duct epithelia
[175]. Activated but not quiescent hepatic stellate cells
express NTPDase2 at the protein level [176]. Only low
expression of NTPDase3 could be demonstrated at the
mRNA level in the liver [50, 177].
NTPDase2 expression in portal ﬁbroblasts, the
primary ﬁbroblastic cell type of the portal area, sug-
gests a role in the regulation of bile ductular signaling
and secretion [161, 175]. Jhandier et al. tested the
hypothesis that portal ﬁbroblast NTPDase2 regulates
epithelial cell proliferation. Using co-cultures of chol-
angiocytes (Mz-ChA-1 human cholangiocarcinoma
cells) and primary portal ﬁbroblasts from rat liver,
increased NTPDase2 expression decreased cell prolif-
eration, and knockdown of NTPDase2 by siRNA
increased proliferation. P2 receptor blockade also
attenuated Mz-ChA-1 proliferation [117]. These exper-
iments deﬁned a novel cross-talk signaling pathway
between bile duct epithelial cells and underlying portal
ﬁbroblasts, regulated by NTPDase2. Because they are
the chief ﬁbrogenic cells of the liver, hepatic stellate
cells and portal ﬁbroblasts are important targets of
liver disease therapy. Loss of NTPDase2 expression in
human biliary cirrhosis, as well as in models of bile
duct ligation in rat, has been observed. NTPDase2
expression also shifts from the portal area to bridging
ﬁbrous bands in cirrhosis with hepatitis C [99].
Functional ATPases were previously shown to be
associated with bile canalicular plasma membranes by
histochemical techniques [178]; the corresponding
enzyme was subsequently incorrectly identiﬁed as
cCAM105 [179–181]. More recent studies revealed
that the canalicular ecto-ATPase corresponds to
NTPDase8 [52], also referred to as hepatic ATP
diphosphohydrolase (ATPDase) [174, 182]. NTPDase8
is the mammalian orthologue of the chicken ecto-
ATPDase cloned from oviduct and liver [183, 184]. In
tandem with ecto-50-nucleotidase, NTPDase8 has the
potential to regulate the concentration of nucleotides
in the hepatic canalicule. The ultimate generation of
extracellular adenosine from dephosphorylated ATP
not only activates adenosine receptors but also pro-
duces the key molecule for purine salvage and
consequent replenishment of ATP stores within many
cell types [17, 185]. Adenosine transporters are of
major importance to organs and cells incapable of de
novo nucleotide synthesis such as brain, muscle,
intestinal mucosa and bone marrow [167, 186]. As the
liver appears to be a major source of purines for these
tissues, curtailment of nucleotide loss into the bile may
be important to maintain appropriate nucleotide/
nucleoside concentrations within hepatocytes [185].
Thus, dephosphorylation of nucleotides by ectonucleo-
tidases may be critical for appropriate systemic purine
homeostasis [167]. The presence of NTPDase8, ecto-
50-nucleotidase and nucleoside transporters in the
canalicular domain of hepatocytes would be consistent
with an important role of NTPDase8 in purine salvage.
The exocrine pancreas
The exocrine pancreas secretes digestive enzymes and
a HCO3-rich ﬂuid. Acini release ATP and the excur-
rent ducts express several types of P2 receptors [187,
188]. Thus ATP may function as a paracrine mediator
between pancreatic acini and ducts. Ectonucleotidase
activity in pancreatic tissues was ﬁrst detected in the
rat in the 1960s [189, 190], followed by analyses in the
pig [191, 192]. Cytochemical and biochemical observa-
tions have corroborated the association of ATPase
activity with zymogen granules [193]. In other studies
of small intercalated/interlobular ducts, NTPDase1
immuno-ﬂuorescence can be localized on the luminal
membranes, while in larger ducts it is localized on the
basolateral membranes [194]. Upon stimulation with
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NTPDase1 relocalized in clusters towards the lumen
and is secreted into the pancreatic juice, as an active
form associated with particulate fractions [188, 195].
As revealed by electron microscopy, NTPDase2 is
located on epithelial cells, myoepithelial cells and
the basolateral membrane of acini. Interestingly,
NTPDase2 could be also detected at the basolateral
surface of endothelial cells [194].
Salivary glands
There are only few studies on the localization of
NTPDases in salivary glands. NTPDases might play a
role in the transport of electrolytes by modulating the
extracellular ATP concentration in the salivary gland
ducts. NTPDase1 reveals to be mainly vascular in
expression. NTPDase2 was immunodetected on myo-
epithelial cells and in nerves [194, 196]. The immuno-
localization of NTPDases 3 and 8 in salivary glands has
not yet been determined.
Kidney
The kidney reveals a complex cellular proﬁle of
expression for P1 and P2 receptors as well as of
ectonucleotidases. Both ATP and adenosine have been
invoked in the regulation of tubuloglomerular feed-
back [197, 198]. This feedback system links the salt
concentrations in the tubular ﬂuid at the macula densa
to the vascular tone of the afferent arteriole of the
same nephron. As depicted by their localization,
NTPDases may participate in the regulation of several
biological functions of the kidney, including vascular
perfusion. In mouse, rat and porcine kidneys, NTP-
Dase1 can be detected in vascular structures, including
blood vessels of glomerular and peritubular capillaries
[174, 199, 200]. NTPDase2 is detected on the Bow-
man’s capsules of mouse and rat [199] and NTPDase8
on the luminal side of porcine renal tubules [174].
More recently, an immunohistochemical analysis of
various ectonucleotidases of the rat nephron revealed
expression of both NTPDase2 and NTPDase3 in the
thick ascending limb, the distal tubule and the inner
medullary collecting ducts. In addition, NTPDase3 is
located in the cortical and outer medullary collecting
ducts [201].
The nervous system
All cell types of the nervous system express nucleotide
receptors [2]. It is increasingly apparent that NTP-
Dases are distributed in the nervous system as ubiqui-
tously as are P2 receptors and that these ectoenzymes
are directly involved in the control of P2 receptor
function in nervous tissues [22, 31, 36]. Signaling via
nucleotides is widespread both in the peripheral and
central nervous system. Major nucleotide receptor-
mediated functions in the central nervous system
include the modulation of synaptic signal transmission
[202], the propagation of Ca
2+ waves between glial
cells [203], or the control and activation of astrocytes
and microglia [204, 205]. In addition, ATP can
contribute to synaptic signal transmission [36]. In the
sympathetic nervous system, ATP acts as a fast neuro-
transmitter together with catecholamines [206], it is an
important mediator of central and peripheral chemo-
sensory transduction, including pain [207] and it is
involved in the control of myelination formation of
peripheral axons [208].
Central nervous system
ATP can be rapidly hydrolyzed to adenosine at brain
synapses that in turn activates pre- or postsynaptic
receptors, thereby modulating neuronal transmission.
Adenine nucleotides undergo conversion to adenosine
within a few hundred milliseconds in the extracellular
(synaptic) space of rat brain slices [209, 210]. Complex
synaptic interactions in the central nervous system may
thus be modulated both by the activation of P2 and
(after hydrolysis of the nucleotide) P1 receptors that
may be located at identical or different cellular targets
[202, 211].
Based on immunoblotting and in situ hybridization,
NTPDase1, 2 and 3 are expressed in the mammalian
brain [47, 57, 59, 116, 177, 212]. NTPDase1 and 2 have
been puriﬁed from porcine brain [213, 214]. But the
exact cellular allocation of individual subtypes is still a
challenge. There is ample evidence from early enzyme
histochemical investigations that surface-located cata-
lytic activity for the hydrolysis of nucleoside tri- and
diphosphates can be allocated to all cell types of the
nervous system [for reviews see 22, 31, 36, 215]. This
catalytic activity can be localized to synapses, including
the synaptic cleft, at the surface of neurosecretory
nerve terminals in the pituitary or at peripheral nerve
terminals. These data imply a wide distribution of cell
surface-located ATP hydrolyzing activity in the CNS.
Neurons
Ecto-ATPase activity has been observed in synapto-
somal fractions isolated from various sources, implying
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Biochemical studies on isolated synaptosomes permit
the determination of the ratios of ATP to ADP
hydrolysis rates as well as the analysis of product
formation. Total synaptosome fractions isolated from
rat brain cortex and immunopuriﬁed cholinergic stria-
tal synaptosomes revealed ratios of 3.4: 1 and 2.1: 1,
respectively [216]. ADP was found to transiently
accumulate after addition of ATP, and was subse-
quently metabolized to AMP and adenosine. Similar
results were obtained with hippocampal synaptosomes
[217]. This strongly argues against a major contribution
by NTPDase1 and NTPDase2 and would rather be
compatible with a neuronal expression of NTPDase3
(comp. Fig. 2). A recent immunocytochemical study
allocates NTPDase3 to neurons including axon-like
structures of various brain regions [218].
Astrocytes, oligodendrocytes, and microglia
The ratio of ATP to ADP hydrolysis is clearly
different in cultured astrocytes. Astrocytes cultured
from cortex or hippocampus display a ratio of 8: 1
[219]. Furthermore, cultured rat cortical astrocytes
accumulate ADP from ATP that is only very slowly
further degraded to AMP [220]. This would be largely
compatible with NTPDase2 as the major ectonucleo-
tidase of cultured astrocytes. Immunocytological inves-
tigations of adult rat and mouse brain sections assign
NTPDase2 solely to the astrocyte-like stem cells in the
subventricular zone of the lateral ventricles and the
dentate gyrus of the hippocampus and to astrocytes in
few distinct additional brain regions [221, 222]. Thus,
cultured astrocytes may reveal functional properties
that differ from the in situ situation as they tend to
rapidly alter their protein expression proﬁle [223].
Enzyme histochemistry assigns ecto-ATPase activity
to both central and peripheral myelin [31], but fully
supplementary immunocytochemical data are lacking.
Enzyme histochemical staining for surface-located
nucleoside diphosphate activity has long been used to
identify microglia in tissue sections of the adult and
developing brain [224]. The major microglial ectonu-
cleotidase has been identiﬁed as NTPDase1 [225].
Stem cells in the adult mammalian brain
In the adult rodent brain, neurogenesis persists in two
restricted regions, the subventricular zone (SVZ) of
the lateral ventricles and the dentate gyrus of the
hippocampus. These regions contain stem cells that
give rise to neurons throughout the life span of the
animal. Interestingly, these cells share astrocytic prop-
erties [226]. They generate highly proliferating inter-
mediate cell types and ﬁnally mature neurons.
NTPDase2 is highly and selectively expressed by the
stem cells (type B cells) of the SVZ [221] (Fig. 5)a s
well as by the progenitor cells (residual radial glia) of
the dentate gyrus [222]. In the presence of epidermal
growth factor (EGF) and ﬁbroblast growth factor-2
(FGF-2), SVZ-derived stem cells can be cultured as
free ﬂoating cellular aggregates (neurospheres). Cul-
tured stem cells express NTPDase2 and functional P2
receptors. Agonists of P2Y1 and P2Y2 receptors
augment cell proliferation, whereas inhibition of the
receptors attenuates cell proliferation in spite of the
presence of mitogenic growth factors [227]. These data
suggest that NTPDase2 and nucleotides, together with
other signaling pathways, contribute to the control of
neurogenesis in the adult mammalian brain.
Apparently, individual enzyme isoforms govern cell
surface-located nucleotide hydrolysis in the various cell
Fig. 5 Detail of arrangement of neuronal stem cells and neuroblasts at the lateral lining of the mouse subventricular zone (SVZ)( triple
labeling). A) DAPI staining of all nuclei. Arrow heads mark endymal lining. B) Stem cells (type B cells) immunopositive for
NTPDase2 form tube-like sheeths around clusters of migrating immature neurons (type A cells) that immunostain for the
microtubule-associated protein doublecortin (DCX) (C). The spaces covered by type A cells remain dark in (B) and are indicated with
stars. D) Merge of B) and C). E) Merge of A), B) and C). Bar =1 0mm. (by courtesy of David Langer, Frankfurt am Main).
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exclude however, the possibility that individual cell
types express more than one isoform with one of the
enzymes predominating. For example, PC12 cells
express mRNA for NTPDase1-3. But the ATP/ADP
hydrolysis ratio, the pattern of product formation and
the immunocytochemical surface staining suggest that
NTPDase3 is the major functional isoform [59, 228].
Similarly cultured normal and immortalized pituitary
and hypothalamic cells express NTPDase1-3 [116]. The
future planned use of transgenic mice expressing ﬂuo-
rescent protein under the promoter of the respective
NTPDase isoform will greatly facilitate the identiﬁca-
tion of the expression pattern of individual enzyme
isoforms in the developing and adult nervous system.
Peripheral nervous system
Noradrenaline and ATP are co-released from sympa-
thetic nerve terminals of the guinea pig heart whereby
ATP enhances noradrenaline release by a mechanism
controlled by ectonucleotidases, possibly NTPDase1
[229]. Interestingly, stimulated sympathetic nerves of
the guinea pig vas deferens release not only ATP and
noradrenaline but also enzyme activity that degrades
ATP to adenosine. The latter exhibits similarities to
NTPDases and ecto-50-nucleotidase but their molecu-
lar identity has not been deﬁned [230].
NTPDase2 associates with immature and non-myeli-
nating Schwann cells of peripheral nerves whereas
NTPDase1 immunoreactivity is absent [231]. NTP-
Dase2 is also expressed by the satellite glial cells in
dorsal root ganglia and sympathetic ganglia and by the
enteric glia surrounding cell bodies of ganglionic
neurons of the myenteric and submucous plexus [231].
Sensory systems
The most comprehensive investigation of expression of
NTPDases within sensory systems concerns the inner
ear. Ectonucleotidase activity is associated with the
tissues lining the perilymphatic compartment of the
cochlea [232, 233]. Immunohistochemical analysis of
the murine cochlea has assigned NTPDase1 to the
cochlear vasculature and primary auditory neurons in
the spiral ganglion, whereas NTPDase2 is associated
with synaptic regions of the sensory inner and outer
hair cells, supporting cells of the organ of Corti and
additional tissue elements [234, 235]. Interestingly,
noise exposure induces upregulation of NTPDase1
and NTPDase2 in the rat cochlea [236].
Taste buds transduce chemical signals in the mouth
into neural messages. Taste cells and nerve ﬁbers
express P2X2 and P2X3 receptors [237] and various
P2Y receptors [238, 239]. Genetic elimination of P2X2
and P2X3 receptors revealed that ATP is a key neu-
rotransmitter in this system [240]. NTPDase2 is ex-
pressed at the mRNA level in mouse taste papillae
[241]. Immunohistochemistry and enzyme histochemi-
cal staining allocate NTPDase2 to type I Fglial-like_
cells in the tongue, palate and larynx. Furthermore,
NTPDase2 immunostaining is associated with nearby
nerves, suggestive of Schwann cells, implying that
NTPDase2 may be a regulator in deﬁned taste
transmission.
Pathological implications
Cerebral ischemia
The interruption of blood ﬂow accompanied by an
interrupted supply of oxygen and glucose initiates a
sequence of events resulting in structural and func-
tional damage of the nervous tissue, comparable to
that seen at other sites of vascular injury [20].
Transient global cerebral ischemia of the rat results
in a long-term increase in extracellular nucleotide
hydrolysis pathways [242, 243]. Preconditioning delays
the postischemic increase in ATP diphosphohydrolase
activity [243]. During the days following transient
forebrain ischemia, mRNA for NTPDase1 (but not of
NTPDase2) and ecto-50-nucleotidase becomes upregu-
lated in the hippocampus [242], corresponding to the
upregulation of the entire ectonucleotidase chain for
the hydrolysis of ATP to adenosine. The data suggest
that the increased expression of ectonucleotidases in
the regions of damaged nerve cells is associated with
activated glia, mainly microglia [224].
The upregulation of the ectonucleotidase chain is
suggestive of an ischemia-induced increased and
sustained cellular release of nucleotides. This could
have several functional implications. Since microglial
cells express the cytolytic P2X7 receptor [244, 245] the
activity of these cells may be particularly endangered
by increased levels of extracellular ATP. Enhanced
activity of NTPDase1 may prevent activated microglia
from overstimulation by ATP released from the
injured tissue. Alternatively, microglial expression of
NTPDase1 might contribute to preventing receptor
desensitization on prolonged exposure to elevated
ATP levels. The parallel increase in activity of ecto-
50-nucleotidase would facilitate the formation of the
ﬁnal hydrolysis product adenosine that exerts neuro-
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tributes to the protection of neurons.
Alterations following plastic changes in the
nervous system
Additional experiments, analyzing synaptosome frac-
tions, suggest that changes in neural plasticity can be
paralleled by changes in ecto-ATPase activity. Enzyme
activity is reduced following avoidance learning [246]
and status epilepticus [247, 248]. It is altered in two rat
models of temporal lobe epilepsy [249], and on pen-
tylenetetrazol kindling [250]. Changes in synaptosomal
ectonucleotidase activity have been implicated by a
broad variety of additional treatments including acute
caffeine treatment [251]. Taken together, these experi-
ments suggest that expression of ectonucleotidases can
be altered following a variety of physiological or path-
ological stimuli, possibly together with that of purine
receptors. Further work needs to deﬁne the enzyme
subtypes involved and the mechanisms underlying the
regulation of ectonucleotidase expression.
Conclusions
This review summarizes components of extracellular
nucleotide-mediated signaling pathways that are
impacted upon largely by the E-NTPDase family
of ectonucleotidases. Modulated, distinct NTPDase
expression appears to regulate nucleotide-mediated
signaling in essentially every tissue, including the
vasculature and of immune and nervous systems.
For example, extracellular nucleotide-mediated vas-
cular endothelial and accessory cell stimulation might
have important consequences for platelet activation,
thrombogenesis, angiogenesis, vascular remodeling and
the metabolic milieu of the vasculature, in response to
inﬂammatory stress and/or immune reactions.
Nucleotides are also of signiﬁcant relevance for the
communication of nerve cells and glial cells or in the
reciprocal signaling between these cells. These puri-
nergic mechanisms might also dictate pathological
processes of the nervous system or following vascular
injury, thromboregulatory disturbances, and defective
angiogenesis with associated perturbations in tissue
remodeling and regeneration.
There is a wide ﬁeld for future investigations of the
role of nucleotides and ectonucleotidases in other
tissues. Increasing interest in this ﬁeld may open up
new avenues for investigation and the development of
new treatment modalities for a large variety of
diseases, including neurological pathological states,
vascular thrombotic disorders including stoke, athero-
sclerosis and the vascular inﬂammation seen in trans-
plant-graft failure.
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